Viewpoint | Published:

Fenretinide and risk reduction of second breast cancer

Nature Clinical Practice Oncology volume 4, pages 6465 (2007) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. (2004) How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci 61: 1475–1484

  2. 2.

    et al. (1995) Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth Differ 6: 863–869

  3. 3.

    et al. (1995) Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 13: 1578–1583

  4. 4.

    et al. (1999) Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91: 1847–1856

  5. 5.

    et al. (2002) Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol 86: 24–27

  6. 6.

    et al. (2006) Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 7: 1065–1071

  7. 7.

    et al. (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18: 801–831

  8. 8.

    et al. (2003) Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res 9: 2032–2039

  9. 9.

    et al. (2005) Sensitivity to DNA damage is a common component of hormone-based strategies for protection of the mammary gland. Mol Cancer Res 8: 435–442

  10. 10.

    et al. (2005) N-(4-Hydroxyphenyl) retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carcinogenesis 26: 1000–1007

  11. 11.

    et al. (1992) Comparative teratogenicity of nine retinoids in the rat. Int J Exp Pathol 73: 551–563

Download references

Author information


  1. A Decensi is Director of, and S Zanardi and A Argusti work in, the Division of Medical Oncology, E.O. Ospedali Galliera, Genoa. B Bonanni is Co-Director of the Division of Chemoprevention, and U Veronesi is Scientific Director of the European Institute of Oncology, and A Costa is Director of the European School of Oncology, Milan, Italy.

    • Andrea Decensi
    • , Silvia Zanardi
    • , Alessandra Argusti
    • , Bernardo Bonanni
    • , Alberto Costa
    •  & Umberto Veronesi


  1. Search for Andrea Decensi in:

  2. Search for Silvia Zanardi in:

  3. Search for Alessandra Argusti in:

  4. Search for Bernardo Bonanni in:

  5. Search for Alberto Costa in:

  6. Search for Umberto Veronesi in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Andrea Decensi.

Supplementary information

About this article

Publication history





Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing